Survival outcomes following stereotactic MR guided adaptive radiation therapy (SMART) in medically inoperable pancreatic cancer.

786 Background: There is ongoing interest in randomized studies utilizing stereotactic MR guided adaptive radiation therapy (SMART) in patients with medically inoperable pancreatic cancer. This study evaluates overall survival (OS) from diagnosis and from the end of radiation treatment (RT) of patients with medically inoperable pancreatic cancer. Methods: A retrospective review analyzed medically inoperable pancreatic cancer patients treated with 50 Gy in 5 fractions of SBRT at a single urban medical center. OS was calculated from diagnosis and end of RT to the date of death or last follow-up. Kaplan-Meier estimates and 95% confidence intervals (CI) were reported, and the Kaplan-Meier curves were compared using log rank tests. Cox’s proportional hazard model was used to determine the combined impact of Zubrod performance status (PS) (0-1 vs. 2-3) and tumor size (TS) at diagnosis (